Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trialResearch in context

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trialResearch in context

Summary: Background: Booster vaccination is an efficient way to address the waning protection of vaccines and immune escape of SARS-CoV-2 variants. We aimed to assess the safety and immunogenicity of SCTV01C, a novel bivalent protein vaccine as a booster for people who previously received two doses...

Full description

Bibliographic Details
Main Authors: Suad Hannawi, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Dongfang Liu, Lixin Yan, Liangzhi Xie
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:EBioMedicine
Subjects:
Safety
Immunogenicity
SARS-CoV-2
Bivalent protein vaccine
Booster
SCTV01C
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422005680

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422005680

Similar Items